Becton, Dickinson and Company Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
May 02, 2024 at 06:30 am EDT
Share
Becton, Dickinson and Company reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported sales was USD 5,045 million compared to USD 4,821 million a year ago. Net income was USD 537 million compared to USD 460 million a year ago. Basic earnings per share from continuing operations was USD 1.85 compared to USD 1.54 a year ago. Diluted earnings per share from continuing operations was USD 1.85 compared to USD 1.53 a year ago.
For the six months, sales was USD 9,751 million compared to USD 9,407 million a year ago. Net income was USD 818 million compared to USD 969 million a year ago. Basic earnings per share from continuing operations was USD 2.82 compared to USD 3.25 a year ago. Diluted earnings per share from continuing operations was USD 2.81 compared to USD 3.24 a year ago.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
